Neuralink’s valuation, last formally set near $9.6 billion in its June 2025 Series E round, now trades on secondary markets at estimates ranging from $24 billion to $42 billion as of late September 2026, reflecting strong trader demand for pre-IPO exposure. Recent sector momentum stems from Precision Neuroscience’s $250 million Series D at just over $1 billion, which drew high-profile capital including Bill Ackman and underscored broader investor appetite for brain-computer interface technologies. With the October 31 resolution date approaching, any new secondary transaction data, clinical trial updates, or Elon Musk announcements could shift implied probabilities in the near term, though private-company marks remain sensitive to limited liquidity and forward-looking sentiment rather than realized revenue.